These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 10905554)

  • 41. Specific inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by liposomally endocapsulated antisense phosphorothioate oligonucleotides: penetration and localization of oligonucleotides in clone 76 cells.
    Hatta T; Takai K; Nakada S; Yokota T; Takaku H
    Biochem Biophys Res Commun; 1997 Mar; 232(2):545-9. PubMed ID: 9125219
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of hepatitis B virus in vitro by antisense oligonucleotides.
    Yao ZQ; Zhou YX; Guo J; Feng ZH; Feng XM; Chen CX; Jiao JZ; Wang SQ
    Acta Virol; 1996 Feb; 40(1):35-9. PubMed ID: 8886096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Liposomal delivery of a 30-mer antisense oligodeoxynucleotide to inhibit proopiomelanocortin expression.
    Fresta M; Chillemi R; Spampinato S; Sciuto S; Puglisi G
    J Pharm Sci; 1998 May; 87(5):616-25. PubMed ID: 9572914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
    Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
    Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
    [TBL] [Abstract][Full Text] [Related]  

  • 45. beta-Cyclodextrin derivatives as carriers to enhance the antiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence.
    Abdou S; Collomb J; Sallas F; Marsura A; Finance C
    Arch Virol; 1997; 142(8):1585-602. PubMed ID: 9672621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antisense approaches for investigating mechanisms of abnormal development.
    Augustine K
    Mutat Res; 1997 Dec; 396(1-2):175-93. PubMed ID: 9434868
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Delivery systems for antisense oligonucleotides.
    Garcia-Chaumont C; Seksek O; Grzybowska J; Borowski E; Bolard J
    Pharmacol Ther; 2000; 87(2-3):255-77. PubMed ID: 11008003
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fluorescent probe and permeability to cells of isopoly (S-carboxymethyl-L-cysteine) derivative of nucleic acid bases.
    Kitaoka S; Tohnai N; Inaki Y; Hatae T; Tanabe T
    Nucleic Acids Symp Ser; 1999; (42):91-2. PubMed ID: 10780394
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lipid-based formulations of amphotericin B.
    Swenson CE; Bolcsak LE; Perkins WR; Janoff AS
    J Antimicrob Chemother; 1995 May; 35(5):709-13. PubMed ID: 7592188
    [No Abstract]   [Full Text] [Related]  

  • 50. Methylphosphonodiester/phosphodiester chimeric oligodeoxynucleotides.
    Tidd DM
    Biochem Soc Trans; 1992 Nov; 20(4):746-9. PubMed ID: 1487055
    [No Abstract]   [Full Text] [Related]  

  • 51. Natural polyphenol assisted delivery of single-strand oligonucleotides by cationic polymers.
    Shen W; Wang R; Fan Q; Li Y; Cheng Y
    Gene Ther; 2020 Aug; 27(7-8):383-391. PubMed ID: 32366887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adsorption of antisense oligonucleotides targeting malarial topoisomerase II on cationic nanoemulsions optimized by a full factorial design.
    Bruxel F; Bochot A; Diel D; Wild L; Carvalho EL; Cojean S; Loiseau PM; Fattal E; Teixeira HF
    Curr Top Med Chem; 2014; 14(9):1161-71. PubMed ID: 24678706
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides.
    Chirila TV; Rakoczy PE; Garrett KL; Lou X; Constable IJ
    Biomaterials; 2002 Jan; 23(2):321-42. PubMed ID: 11761152
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Uptake and intracellular distribution of oligonucleotides vectorized by a PAMAM dendrimer.
    Hélin V; Gottikh M; Mishal Z; Subra F; Malvy C; Lavignon M
    Nucleosides Nucleotides; 1999; 18(6-7):1721-2. PubMed ID: 10474256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The state of the art in antisense research.
    Wagner RW
    Nat Med; 1995 Nov; 1(11):1116-8. PubMed ID: 7584973
    [No Abstract]   [Full Text] [Related]  

  • 56. Oligonucleotides and polynucleotides as biologically active compounds.
    Vlassov VV; Vlassova IE; Pautova LV
    Prog Nucleic Acid Res Mol Biol; 1997; 57():95-143. PubMed ID: 9175432
    [No Abstract]   [Full Text] [Related]  

  • 57. Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery.
    Yu H; Zou Y; Wang Y; Huang X; Huang G; Sumer BD; Boothman DA; Gao J
    ACS Nano; 2011 Nov; 5(11):9246-55. PubMed ID: 22011045
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anthrapyridones, a novel group of antitumour non-cross resistant anthraquinone analogues. Synthesis and molecular basis of the cytotoxic activity towards K562/DOX cells.
    Tarasiuk J; Stefańska B; Plodzich I; Tkaczyk-Gobis K; Seksek O; Martelli S; Garnier-Suillerot A; Borowski E
    Br J Pharmacol; 2002 Mar; 135(6):1513-23. PubMed ID: 11906965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A cationic derivative of amphotericin B as a novel delivery system for antisense oligonucleotides.
    Garcia-Chaumont C; Seksek O; Jolles B; Bolard J
    Antisense Nucleic Acid Drug Dev; 2000 Jun; 10(3):177-84. PubMed ID: 10905554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression.
    Alahari SK; DeLong R; Fisher MH; Dean NM; Viliet P; Juliano RL
    J Pharmacol Exp Ther; 1998 Jul; 286(1):419-28. PubMed ID: 9655887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.